Skip to main content
SpringerLink
Log in

Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

One hundred and forty-four evaluable patients with recurrent or metastatic renal cell carcinoma (RCC) were treated with vinblastine infusion (n = 35), L-alanosine (n = 36), acivicin (n = 27), or aminothiadiazole (n = 46). Observed objective response rates of 9%, 3%, 4%, and 2%, respectively indicate that none of these agents has significant antineoplastic activity in recurrent or metastatic RCC. Multivariate analysis of survival data suggests that initial performance status, time from initial diagnosis to study entry, and the presence or absence of lung metastases are important prognostic factors for survival. After adjustment for these factors, treatment assignment was also seen to be of prognostic value. All four treatments were generally well tolerated. There were no reports of life-threatening or lethal toxicities; however, 37% of the patients experienced severe reactions to treatment, primarily myelosuppression, anemia, neuropathies, and mucositis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Silverberg E: Cancer statistics, 1984. CA — A Cancer Journal for Clinicians 34:7–23, 1984

    Google Scholar 

  2. Hrushesky WJ, Murphy GP: Current status of the therapy of advanced renal cell carcinoma. J Surg Oncol 9:277–288, 1977

    Google Scholar 

  3. Harris DT: Hormonal therapy and chemotherapy of renal cell carcinoma. Semin Oncol 10:422–430, 1983

    Google Scholar 

  4. Krown SE: Therapeutic options in renal cell carcinoma. Semin Oncol 12:13–17, 1985

    Google Scholar 

  5. Rinehart J, Malspeis L, Young D, Neidhart J: Phase I/II trial of recombinant β-interferon serine in patients with renal cell carcinoma. Cancer Res 46:5364–5367, 1986

    Google Scholar 

  6. Brown TD, Koeller J, Beougher K, Golando J, Bonnem EM, Spiegel R, Von Hoff DD: Phase I clinical trial of recombinant DNA gamma Interferon. J Clin Oncol 5:790–798, 1987

    Google Scholar 

  7. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 313:1485–1492, 1985

    Google Scholar 

  8. Hahn RG, Temkin NR, Savlov ED, Perlia C, Wampler GL, Horton J, Marsh J, Carbone PP: Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. Cancer Treat Rep 62:1093–1095, 1978

    Google Scholar 

  9. Hahn RG, Bauer M, Wolter J, Creech R, Bennett JM, Wampler G: Phase II study of single agent therapy with megestrol acetate, VP-16–213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer. Cancer Treat Rep 63:513–515, 1979

    Google Scholar 

  10. Hahn RG, Begg CB, Davis T: Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer. Cancer Treat Rep 65:711–713, 1981

    Google Scholar 

  11. Earhart RH, Elson PJ, Rosenthal SN, Hahn RG, Slayton RE: Phase II study of PALA and AMSA in advanced renal cell carcinoma. Am J Clin Oncol (CCT) 6:555–560, 1983

    Google Scholar 

  12. Glover D, Trump D, Kvols L, Elson P, Vogl S: Phase II trial of misonidazole (miso) and cyclophosphamide (cyc) in metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 12:1405–1408, 1986

    Google Scholar 

  13. Elson PJ, Earhart RH, Kvols LK, Spiegel R, Keller A, Kies MS, Davis TE, Stevens C, Gumas L, Trump DL: Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. Cancer Treat Rep 71:331–332, 1987

    Google Scholar 

  14. Jackson DV, Bender RA: Cytotoxic thresholds of vincristine in a murine and human leukemia cell line in vitro. Cancer Res 39:4346–4349, 1979

    Google Scholar 

  15. Yap H-Y, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL: Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64:279–283, 1980

    Google Scholar 

  16. Graff JC, Plagemann PG: Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate. Cancer Res 36:1428–1440, 1976

    Google Scholar 

  17. Hurlbert RB, Zimmerman CJ, Carrington DB: Inhibition of adenylosuccinate synthetase by a metabolite of alanosine. Abstract in Proc Am Assoc Cancer Res & Am Soc Clin Oncol 18:234, 1977

    Google Scholar 

  18. Tyagi AK, Cooney DA, Bledsoe RK, Johnson RK, Wood HB: Studies on the mechanism of action of L-alanosine. Abstract in Proc Am Assoc Cancer Res & Am Soc Clin Oncol 20:98, 1979

    Google Scholar 

  19. Nelson JA, Rose LM, Bennett LL: Mechanism of action of 2-amino-1,3,4-thiadiazole (NSC 4728). Cancer Res 37:182–187, 1977

    Google Scholar 

  20. O'Dwyer M, Alonso T, Leyland-Jones B. Acivicin: a new glutamine antagonist in clinical trials. J Clin Oncol 2:1064–1071, 1984

    Google Scholar 

  21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (CCT) 5:649–655, 1982

    Google Scholar 

  22. Krakoff IH, Balis ME: Studies of the uricogenic effect of 2-substituted thiadiazoles in man. J Clin Invest 38:907–915, 1959

    Google Scholar 

  23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958

    Google Scholar 

  24. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 50:163–170, 1966

    Google Scholar 

  25. Cox DR: Regression models and life tables. J Royal Stat Soc B 34:187–202, 1972

    Google Scholar 

  26. Duebler JP, Hogan TF, Trump DL, Bryan GT: Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma. Cancer Treat Rep 68:925–926, 1984

    Google Scholar 

  27. Tannock IF, Evans WK: Failure of 5-day vinblastine infusion in the treatment of patients with renal cell carcinoma. Cancer Treat Rep 69:227–228, 1985

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, CA 23318, Boston, MA, USA

    Paul J. Elson

  2. Mayo Clinic, CA 13650, Rochester, MN, USA

    Larry K. Kvols, Richard G. Hahn & John D. Earle

  3. Albert Einstein College of Medicine, CA 14958, Bronx, NY, USA

    Steven E. Vogl

  4. Hospital of the University of Pennsylvania, CA 15488, Philadelphia, PA, USA

    Donna J. Glover

  5. University of Wisconsin Clinical Cancer Center, CA 21076, Madison, WI, USA

    Donald L. Trump, Paul P. Carbone & Thomas E. Davis

Authors
  1. Paul J. Elson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larry K. Kvols
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven E. Vogl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Donna J. Glover
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Richard G. Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Donald L. Trump
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paul P. Carbone
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John D. Earle
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Thomas E. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elson, P.J., Kvols, L.K., Vogl, S.E. et al. Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Invest New Drugs 6, 97–103 (1988). https://doi.org/10.1007/BF00195367

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00195367

Key words

Search

Navigation